OM:IZAFE B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. More Details


Snowflake Analysis

Overvalued with concerning outlook.

Share Price & News

How has iZafe Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IZAFE B has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-8.6%

IZAFE B

-4.7%

SE Healthcare Services

-0.3%

SE Market


1 Year Return

-16.0%

IZAFE B

-30.9%

SE Healthcare Services

16.9%

SE Market

Return vs Industry: IZAFE B exceeded the Swedish Healthcare Services industry which returned -30.9% over the past year.

Return vs Market: IZAFE B underperformed the Swedish Market which returned 16.9% over the past year.


Shareholder returns

IZAFE BIndustryMarket
7 Day-8.6%-4.7%-0.3%
30 Day-11.3%-9.7%1.1%
90 Day15.7%-3.3%6.5%
1 Year-16.0%-16.0%-30.6%-30.9%19.1%16.9%
3 Year-73.6%-73.6%-45.8%-46.5%36.4%21.8%
5 Year58.8%58.8%11.1%9.5%65.7%33.6%

Price Volatility Vs. Market

How volatile is iZafe Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is iZafe Group undervalued compared to its fair value and its price relative to the market?

4.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IZAFE B's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IZAFE B's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IZAFE B is unprofitable, so we can't compare its PE Ratio to the XE Healthcare Services industry average.

PE vs Market: IZAFE B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IZAFE B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IZAFE B is good value based on its PB Ratio (4.3x) compared to the SE Healthcare Services industry average (5.2x).


Next Steps

Future Growth

How is iZafe Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

41.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IZAFE B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IZAFE B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IZAFE B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IZAFE B's revenue (15.1% per year) is forecast to grow faster than the Swedish market (3.1% per year).

High Growth Revenue: IZAFE B's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IZAFE B is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has iZafe Group performed over the past 5 years?

-42.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IZAFE B is currently unprofitable.

Growing Profit Margin: IZAFE B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IZAFE B is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.

Accelerating Growth: Unable to compare IZAFE B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IZAFE B is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-14.9%).


Return on Equity

High ROE: IZAFE B has a negative Return on Equity (-80.73%), as it is currently unprofitable.


Next Steps

Financial Health

How is iZafe Group's financial position?


Financial Position Analysis

Short Term Liabilities: IZAFE B's short term assets (SEK2.7M) do not cover its short term liabilities (SEK20.5M).

Long Term Liabilities: IZAFE B's short term assets (SEK2.7M) do not cover its long term liabilities (SEK5.3M).


Debt to Equity History and Analysis

Debt Level: IZAFE B's debt to equity ratio (34.5%) is considered satisfactory.

Reducing Debt: IZAFE B's debt to equity ratio has increased from 15% to 34.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IZAFE B has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IZAFE B has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.9% each year


Next Steps

Dividend

What is iZafe Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IZAFE B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IZAFE B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IZAFE B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IZAFE B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IZAFE B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Anders Segerstrom (35 yo)

1.75yrs

Tenure

Mr. Anders Segerström serves as the Chief Executive Officer at iZafe Group AB (publ) (formerly known as MediRätt AB (publ)) since 2019. Mr. Segerström has been in leading company roles in the fields of bus ...


Leadership Team

NamePositionTenureCompensationOwnership
Anders Segerstrom
Chief Executive Officer1.75yrsno datano data
Barbro Sjonell
Co-Founderno datano datano data
Mikael Svensson
Chief Operating Officer3.75yrsno datano data
Goran Hermanson
COO & Director1.08yrsno datano data
Tobias Johansson
Sales Manager & VP1.75yrsno datano data

1.8yrs

Average Tenure

45.5yo

Average Age

Experienced Management: IZAFE B's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Goran Hermanson
COO & Director1.08yrsno datano data
Thomas Ahlerup
Acting Chairman of the Board1.75yrsno datano data
Goran Sjonell
Alternate Directorno datano datano data
Carl Sjonell
Director6.75yrsno datano data
Viveca Gyberg
Director2.75yrsno datano data

2.3yrs

Average Tenure

59yo

Average Age

Experienced Board: IZAFE B's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.9%.


Top Shareholders

Company Information

iZafe Group AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iZafe Group AB (publ)
  • Ticker: IZAFE B
  • Exchange: OM
  • Founded: 2008
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: kr115.673m
  • Shares outstanding: 32.77m
  • Website: https://www.izafe.se

Number of Employees


Location

  • iZafe Group AB (publ)
  • Stockholmsvägen 33
  • Lidingö
  • Stockholm County
  • 181 33
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IZAFE BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKApr 2011
M02BST (Boerse-Stuttgart)YesClass B SharesDEEURApr 2011

Biography

iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 21:19
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.